Mohammed Aseeri

Dr. Mohammed Aseeri


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
TATamather Almandeel
Tamather Almandeel
MKMansoor Ahmed Khan
Mansoor Ahmed Khan
AAAshwag Algethami
Ashwag Algethami
MAMashael S. Alaboud
Mashael S. Alaboud
MAMunirah A. Alkathiri
Munirah A. Alkathiri
AAAbdullah Alotaibi
Abdullah Alotaibi
Background: Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-Biosimilar) in 2021. Hence, our practice changed to providing first cycles of IV rituximab (Truxima-Biosimilar) instead of rituximab (Mabthera), and if the first cycle was completed without severe infusion-related reactions (IRRs), then subsequent cycles were given with subcutaneous (SC) rituximab as per institutional guidelines. However, the safety of this approach has not been evaluated. Methods: A retrospective study was conducted at the Princess Nourah Oncology Center in Saudi Arabia. The primary objective was to assess IRRs after using IV rituximab (Truxima-Biosimilar) in the first cycle followed by SC rituximab in subsequent cycles. Results: Of the 71 patients reviewed, 35 patients met the eligibility criteria. Only one (3%) patient developed an IRR. However, it was a Grade 1 IRR, as per CTCAE.V5, and the patient was able to complete the remaining IV infusion successfully. Hence, all patients transitioned from IV rituximab biosimilar to SC rituximab Mabthera. Conclusions: This real-world study demonstrates that transitioning from IV rituximab biosimilar to SC Mabthera is a well-tolerated and safe practice, confirming the extrapolation principle of biosimilars.

14 October 2022 in Cureus
Verified
Journal Article
Open access
SASultan Alotaibi
Sultan Alotaibi
HHHani Hasan
Hani Hasan
HMHend Metwali
Hend Metwali
MAMohammed Aseeri
Mohammed Aseeri
This study was conducted to evaluate the efficacy and safety of apixaban versus warfarin in morbidly obese patients. A total of 250 morbidly obese patients with a body mass index (BMI) higher than 40 kg/m2 or a body weight higher than 120 kg who were on anticoagulation therapy with either apixaban or warfarin for over one month were included in the study. This retrospective cohort, multicenter study was executed using the medical records of 125 morbidly obese patients treated with apixaban, while patients on warfarin were selected using a systemic random sampling to match the sample size of the apixaban group. There was no significant difference between apixaban and warfarin in the development of thromboembolic events and major bleeding. However, incidences of minor bleeding significantly decreased in the apixaban group compared to patients treated with warfarin. This difference was overcome by controlling serum creatinine and nonsteroidal anti-inflammatory drugs (NSAIDs). In conclusion, apixaban efficacy and safety are nearly the same as that of warfarin in morbidly obese patients with a lower incidence of minor bleeding with apixaban. Controlling serum creatinine and NSAIDs use may improve warfarin safety and decrease its complications.

13 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TATamather Almandeel
Tamather Almandeel
MKMansoor Ahmed Khan
Mansoor Ahmed Khan
AAAshwag Algethami
Ashwag Algethami
MAMashael S. Alaboud
Mashael S. Alaboud
MAMunirah A. Alkathiri
Munirah A. Alkathiri
AAAbdullah Alotaibi
Abdullah Alotaibi
Background: Biosimilar versions of Rituximab have the same safety profile and efficacy as the reference prod-uct across all indications for which it is approved based on the extrapolation principle. Our organization had replaced IV Rituximab (Mabthera) with IV Rituximab (Truxima-Biosimilar) in 2021. Hence, practice was changed to give first cycles of IV Rituximab (Truxima-Biosimilar) instead of Rituximab (Mabthera) and if first cycle was completed without severe infusion related reactions (IRRs) then subsequent cycles were given with subcutaneous Rituximab as per institutional guidelines. There is no evidence of the safety of this practice. Therefore, we decided to evaluate the safety of this practice in retrospective fashion. Objective: The primary objective was to assess IRRs after using Rituximab (Truxima-Biosimilar) instead of Rituximab (Mabthera) IV in-jection in the first cycle followed by subcutaneous rituximab in subsequent cycles. While secondary objective was to determine the overall response rate (ORR). Methods: A retrospective observational study was con-ducted at Princess Nourah Oncology Center (PNOC) in Jeddah, Saudi Arabia. Results: Seventy-one patients were reviewed, and 35 patients met the eligibility criteria. Only one (3%) out of 35 patients developed IRR. However, it was only grade 1 IRR as per CTC.AE V5 and this patient was able to complete the rest of Rituxi-mab infusion intravenously (IV) in the first cycle successfully. Hence all patients transitioned from IV Rituxi-mab biosimilar to subcutaneous (SC) Rituximab Mabthera. Conclusions: We conclude from our real-world evidence study that transition from IV Rituximab biosimilar to SC Rituximab Mabthera is well tolerated and safe practice and confirms the extrapolation principle of biosimilars.

8 July 2026 in Global Journal on Quality and Safety in Healthcare
Verified
Journal Article
Open access
MAMohammed Aseeri
Mohammed Aseeri
RBRawan Bukhari
Rawan Bukhari
SBSabirin Bakhsh
Sabirin Bakhsh
MAMarwah Almuzaini
Marwah Almuzaini
STShouq Turkistani
Shouq Turkistani
KAKhulood Abdulghani
Khulood Abdulghani
Introduction: Medication errors represent a global issue that can adversely affect patients and healthcare systems. Inappropriate medication reconciliation (MedRec) is the leading cause of prescribing errors, with over 40% of such incidents. Evidence shows that clinical pharmacy resident-run MedRec programs can identify and resolve unintentional medication discrepancies (UMDs) in 60.2% of patients, demonstrating these services’ potential impact on patient care. This study evaluated clinical pharmacy residents’ impact on MedRec during their clinical rotations in a tertiary care hospital. Methods: This retrospective, observational, single-center study was conducted from November 2021 to the end of March 2022 by four clinical pharmacy residents on adult patients aged 18 years or older who were admitted to the hospital within 48 hours. Data were obtained by using a MedRec form and the hospital’s electronic medical record system during a 5-month period. The primary outcome was to measure clinical pharmacy residents’ impact on the MedRec service by identifying the number and proportion of UMDs observed among admitted patients during residents’ clinical rotations. Results: In total, 205 patients were included, with 193 UMDs identified. Most of the discrepancies were omissions (119 [62%]), followed by non-compliance (20 [11%]), commission (19 [9%]), and duplication (13 [7%]). Healthcare providers accepted 151 (86%) physician-directed interventions. Resumption of medication was the most common intervention, accounting for 66% of all interventions. Conclusion: Clinical pharmacy residents significantly contribute to improving medication safety by detecting and resolving UMDs during patient admission. Their involvement highlights the value of pharmacist-led MedRec and supports its integration as a core element of residency training to reduce adverse drug events and improve outcomes.

14 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SBSabirin Bakhsh
Sabirin Bakhsh
MKMansoor Ahmed Khan
Mansoor Ahmed Khan
MAMajed Alshamrani
Majed Alshamrani
RMRoula Mufti
Roula Mufti
AAAnjum Naeem Ansari
Anjum Naeem Ansari
MAMohammed Aseeri
Mohammed Aseeri
Effectiveness of a Single Fixed Dose 3 mg Rasburicase for Prevention and Management of Hyperuricemia of Tumor Lysis Syndrome in adult Cancer Patients Background: Tumor lysis syndrome (TLS) is a potentially life-threatening complication associated with certain types of cancer. Rasburicase is an essential medicine required to prevent and treat the hyperuricemia associated with TLS. Due to a shortage of rasburicase during the COVID-19 pandemic, a fixed dose strategy of 3 mg rasburicase had been used in many adult cancer patients in our center. Objective: The objective of this study was to assess the effectiveness of a 3 mg fixed dose of rasburicase in preventing and managing hyperuricemia associated with TLS in adult cancer patients. Methods: We conducted a retrospective, observational cohort study between March 2020 and November 2022. The study included adult patients who received a fixed dose of 3 mg rasburicase. The primary outcome measure was the reduction in serum UA levels of